hepatitis c/головная боль

Ссылка сохраняется в буфер обмена

Статьи Клинические испытанияПатенты

Выберите тип сортировки

Страница 1 от 309 полученные результаты

Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

The activity and tolerability of a retreatment cycle with leucocyte interferon-alpha (IFN-alpha) (6 million units (MU) three times weekly for 12 months) was evaluated in a group of 22 hepatitis C patients who had been intolerant to a previous course of lymphoblastoid IFN-alpha. Seven patients (31%)

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Previous studies in Caucasian patients showed treatment of chronic hepatitis C with pegylated interferon/ribavirin was well tolerated, and produced a higher response rate especially in genotype 1 infections. However, it is unknown whether this conclusion can be extrapolated to patients with Chinese

Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE The impact of gastric bypass surgery on the pharmacokinetics of various medications has been reported. Presently, no data exist for the treatment of chronic hepatitis C virus with ledipasvir/sofosbuvir (LDV/SOF) in an individual with a history of gastric bypass. METHODS We report the

Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A 57-year-old man had abnormal hepatic function identified in April 1994. In October 1994, chronic hepatitis C was diagnosed. Based on the findings of a liver biopsy, administration of recombinant interferon (rIFN)-alpha2b was begun. In the 16th week of treatment, the patient experienced headache

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood,

Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Pegylated interferon (peginterferon) and ribavirin combination therapy is used extensively for therapy of chronic hepatitis C. Most patients that receive this therapy are known to develop influenza-like symptoms with fever and headache. Therefore, we attempted to construct a multiple-regression

[Seroprevalence of Hepatitis C Virus (HCV) in patients of the Regional Viral Reference Laboratory (Maracaibo, Venezuela)].

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE Collect and analyze information regarding seroprevalence of Hepatitis C Virus (HCV) in a population of 722 patients that visited the Regional Viral Reference Laboratory (Maracaibo, Venezuela) during the years 2000-2003. METHODS An immunoenzymatic test INNOTEST HCV Ab IV of Innogenetics was

Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Until 2014, pegylated interferon plus ribavirin was the recommended standard of care for the treatment of chronic hepatitis C virus (HCV) infection in India. This open-label phase 3b study, conducted across 14 sites in India between 31 March 2014 and 30 November 2015, evaluated the efficacy and

[A case of chronic hepatitis C complicated by ischemia-like changes seen on the electrocardiogram during interferon treatment].

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A 53-year-old woman was admitted to the hospital for chest pain with headache, nausea and vomiting, two and a half hours after an intramuscular injection of 6 x 10(6) units of IFN (interferon) alpha 2a, in the 11th week of IFN treatment for chronic hepatitis C. The electrocardiogram (ECG) showed ST

A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A 70-year-old man who suffered from chronic hepatitis C was infected with HCV genotype 1 and exhibited a high viral load. He had hypertension and had consumed the equivalent of 50 g of ethanol per day. He was treated with pegylated interferon and ribavirin. After 51 weeks, he developed an unsteady

Frequency of depression and somatic symptoms in patients on interferon alpha/ribavirin for chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND Large numbers of patients suffering from Chronic Hepatitis C (HCV) are seeking treatment with interferon alpha (IFN) because of significant advances in overall improvement in the course of HCV and its complications. Objectives were to estimate the frequency of depression and somatic

Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE A probable case of severe drug-induced hyponatremia associated with boceprevir use is reported. CONCLUSIONS A 55-year-old woman was started on boceprevir (800 mg orally thrice daily) during week 5 of triple therapy for chronic hepatitis C. Her serum sodium concentration the morning before

Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon-alpha.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Common adverse effects of IFN-alpha include flulike symptoms, headache, irritability, and bone marrow suppression. Hepatic side effects are unusual except in patients with pretreatment autoimmune hepatitis. Granuloma formation in the liver as a result of IFN-alpha therapy has never been reported. We

Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

We treated a 67-year-old Japanese woman with membranoproliferative glomerulonephritis (MPGN) and chronic active hepatitis associated with hepatitis C virus (HCV) infection. Treatment commenced with a daily dose of 6 MU IFN alpha-2b for 2 weeks, which was changed to three times weekly thereafter.

Присоединяйтесь к нашей
странице facebook

Herbal & Natural Medicine

Самая полная база данных о лекарственных травах, подтвержденная наукой

Работает на 55 языках
Травяные лекарства, подтвержденные наукой
Распознавание трав по изображению
Интерактивная карта GPS - отметьте травы на месте (скоро)
Прочтите научные публикации, связанные с вашим поиском
Ищите лекарственные травы по их действию
Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.